ARL5A

Across TCGA pan-cancer cohorts, ARL5A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ARL5A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ARL5A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARL5A is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, CCRCC, and LUAD are the cancer types where ARL5A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL5A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	II,III,IV	−0.665	<.001	8	view →
CCRCC	Male	III,IV	+0.395	<.001	6	view →
LUAD	All	All	−0.282	<.001	6	view →
HNSC	Male	All	−0.198	.019	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ARL5A–LSCC

Open the LSCC breakdown →